PMID- 36816461
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230224
IS  - 1745-1981 (Print)
IS  - 1740-4398 (Electronic)
IS  - 1740-4398 (Linking)
VI  - 12
DP  - 2023
TI  - A real-world retrospective study of omeprazole-domperidone combination in 
      managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 
      DiabEtes mellitus (PRIDE-2).
LID - 10.7573/dic.2022-10-3 [doi]
LID - 2022-10-3
AB  - BACKGROUND: Proton-pump inhibitors, along with a prokinetic agent, are widely 
      used to provide symptomatic relief amongst patients with acid peptic disease 
      (APD). This article evaluates the effectiveness and safety of the 
      omeprazole-domperidone combination amongst patients with type 2 diabetes mellitus 
      for the management of APD. METHODS: PRIDE-2 (PRoton-pump Inhibitor in patients 
      with type 2 DiabEtes mellitus) is a retrospective study reviewing electronic 
      medical records of patients with type 2 diabetes mellitus and APD who were 
      receiving the omeprazole-domperidone combination and visiting multiple Indian 
      healthcare settings between March 2018 and April 2021. The effectiveness outcome 
      of the therapy was evaluated in terms of resolution of APD symptoms at visit 5 
      (120 days after baseline visit) compared with visit 1 (baseline visit). Safety 
      was determined in terms of reported adverse events (AEs) during the treatment 
      period (120 days). RESULTS: A total of 174 patients were included in the study. 
      The mean age of the patients was 51.5+/-9.6 years, with the majority (59.8%) being 
      men. A significant proportion of patients reported relief from APD symptoms, 
      including abdominal pain (91.6%), epigastric burning (68.7%), nausea (89.5%), 
      flatulence (100.0%), loss of appetite (93.6%), and altered bowel movements 
      (94.7%) (p<0.001 for each) at visit 5 compared with visit 1. No serious AEs were 
      reported. CONCLUSION: Omeprazole-domperidone combination was beneficial in 
      providing symptomatic relief to patients with diabetes and APD. The combination 
      therapy was well tolerated, with few reports of minor AEs.
CI  - Copyright (c) 2023 Saboo B, Mulwani N, Petare AU, Veligandla KC, Pinto CS, Mane A, 
      Rathod R, Kotak B.
FAU - Saboo, Bharat
AU  - Saboo B
AD  - Department of Diabetology, Prayas Diabetes Centre, Indore, Madhya Pradesh, India.
FAU - Mulwani, Nimmi
AU  - Mulwani N
AD  - Department of Diabetology, Dr. Nimmi's Diabetes Care, Chandkheda, Ahmedabad, 
      Gujarat, India.
FAU - Petare, Anup Uttam
AU  - Petare AU
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
FAU - Veligandla, Krishna Chaitanya
AU  - Veligandla KC
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
FAU - Pinto, Colette Stephen
AU  - Pinto CS
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
FAU - Mane, Amey
AU  - Mane A
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
FAU - Rathod, Rahul
AU  - Rathod R
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
FAU - Kotak, Bhavesh
AU  - Kotak B
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
DEP - 20230213
PL  - England
TA  - Drugs Context
JT  - Drugs in context
JID - 101262187
PMC - PMC9933899
OTO - NOTNLM
OT  - acid peptic disease
OT  - domperidone
OT  - omeprazole
OT  - proton-pump inhibitors
OT  - symptomatic relief
OT  - type 2 diabetes mellitus
COIS- Disclosure and potential conflicts of interest: AUP, KCV and CSP are the Medical 
      Advisor, Team Lead and Clinical Research Specialist, respectively, at Medical 
      Affairs Department, Dr. Reddy's Laboratories Ltd, Hyderabad. AM, RR and BK are 
      Medical Cluster Head, Head Ideation & Clinical Research and Head Medical Affairs, 
      respectively, at the Medi-cal Affairs Department, Dr. Reddy's Laboratories Ltd, 
      Hyderabad. BS and NM have no conflicts of interest to disclose. The International 
      Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests 
      form for the authors is available for download at: 
      https://www.drugsincontext.com/wp-content/uploads/2023/01/dic.2022-10-3-COI.pdf
EDAT- 2023/02/24 06:00
MHDA- 2023/02/24 06:01
PMCR- 2023/02/13
CRDT- 2023/02/23 09:21
PHST- 2022/10/18 00:00 [received]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/02/23 09:21 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/02/24 06:01 [medline]
PHST- 2023/02/13 00:00 [pmc-release]
AID - dic-2022-10-3 [pii]
AID - 10.7573/dic.2022-10-3 [doi]
PST - epublish
SO  - Drugs Context. 2023 Feb 13;12:2022-10-3. doi: 10.7573/dic.2022-10-3. eCollection 
      2023.